Loading
A phase 3 trial of bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin), leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in colorectal cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT04094688 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 455 participants, started 2019-10-29 and due to reach its primary completion in 2024-07-15. Interventions recorded: Bevacizumab; Oxaliplatin; Leucovorin Calcium; Fluorouracil; Irinotecan Hydrochloride; Irinotecan; Cholecalciferol; Quality-of-Life Assessment; Questionnaire Administration. Conditions listed: Colorectal Adenocarcinoma. Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: "* Histologically confirmed advanced/metastatic colorectal adenocarcinoma for which metastasectomy is not planned". Sites: Puerto Rico, United States. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
455 enrolled.
95% CI 10.3 to 13.3; Figures from the ClinicalTrials.gov results section (first posted 2026-03-03), not from a publication · 95% CI 9.4 to 12.2
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | Arm I (Bevacizumab, Chemotherapy, High-dose Vitamin D3) | 228 | 11.8 months | 0.92 (0.73 to 1.16) | 0.25 | link |
| Arm II (Bevacizumab, Chemotherapy, Standard-dose Vitamin D3) | 227 | 10.3 months |
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Alliance for Clinical Trials in Oncology, FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-deep-dive.